AstraZeneca publishes updated results from US-based trial of its COVID-19 vaccine
Primary analysis demonstrated 76% efficacy at preventing symptomatic COVID-19, slightly lower than previously reported 79%, although updated results showed vaccine was consistent at preventing severe or critical disease and hospitalisation, demonstrating 100% efficacy.
Source:
PharmaTimes